| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Halozyme Therapeutics (NASDAQ:HALO) through any online brokerage.
Other companies in Halozyme Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Halozyme Therapeutics has a consensus price target of $85.81.
The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $121.37 last updated October 16, 2026 at 4:29 PM EDT.
There are no upcoming dividends for Halozyme Therapeutics.
Halozyme Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Halozyme Therapeutics.
Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
